<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305110</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 0511307</org_study_id>
    <nct_id>NCT00305110</nct_id>
    <nct_alias>NCT01006850</nct_alias>
  </id_info>
  <brief_title>Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain</brief_title>
  <official_title>Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and speed of onset of 2mg intravenous
      hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency
      department with acute severe pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction and Background: Pain is cited as the most frequent reason for visits to
      emergency departments (EDs) (McCaig, 2001). It can be estimated from the National Hospital
      Ambulatory Medical Care Survey, an annual survey of a representative sample of visits to US
      EDs, that there are 17 million visits per year to US EDs for specific complaints of pain, 29
      million visits including &quot;back symptoms&quot; and &quot;injuries not otherwise specified&quot; as well as
      specific mentions of pain. However it is widely acknowledged that pain is seriously
      under-treated in the ED as well as in other health care settings (Ducharme, 1996; Selbst,
      1990; Wilson, 1989). The concern regarding under-treatment is reflected in new standards for
      pain management developed by the Joint Commission on Accreditation of Healthcare
      Organizations (JCAHO) requiring assessment of pain at triage in the ED and referring to pain
      measurement as the &quot;fifth vital sign&quot; (Philips, 2000).

      Proper pain management is a tremendous challenge to ED physicians as pain is not only a
      noxious experience but also a symptom of injury and disease that needs to be understood and
      appropriately treated. Further complicating pain management is the large interpersonal
      variability in pain perception and expression reflecting cultural, contextual, and individual
      differences between people. Reasons for under-treating pain include concern over side effects
      of opioids, perception of pain complaints as possible drug-seeking behavior, under-staffing,
      concern that analgesics will mask symptoms or delay early diagnosis and treatment, and
      contribute to risks of tolerance and dependence in vulnerable patients.

      Morphine has long been considered the gold standard in pain control. Hydromorphone is another
      powerful opioid that has been used extensively for the management of post-operative pain and
      morphine-resistant cancer-related pain. A recent Cochrane review on the use of hydromorphone
      found 32 studies that focused on acute pain (Quigley, 2003). Of these 32 studies, only 9
      involved intravenous forms of hydromorphone (Coda, 1997; Collins, 1996; Deutsch, 1968;
      Jasani, 1994; Liu, 1995; Mahler, 1975; Rapp, 1996; Searle, 1994; Urquhart, 1988). Of these 8
      studies, 5 involved patient controlled analgesia, and only 1 study compared IV hydromorphone
      to IV morphine (Mahler, 1975). The Cochrane review concludes that there are substantial gaps
      in the understanding of the efficacy and potency of hydromorphone.

      We have recently completed a study in non-elderly adult patients (IRB 04-08-225) that showed
      that weight-based IV hydromorphone provides better pain relief than weight-based IV morphine.
      This result was both statistically and clinically significant. We also demonstrated in this
      same study that IV hydromorphone has a faster onset and also provided statistically
      significant improvement in pain relief at 5 minutes as compared to IV morphine.

      Although weight-based dosing of medications is common in pediatrics, most emergency
      physicians use whole integer amounts of pain medications. IV hydromorphone is more potent
      than IV morphine, so the dosages given are much smaller. We therefore wish to give a standard
      2 mg dose of IV hydromorphone to all non-elderly adult patients weighing at least 150 lbs
      presenting to the ED with acute severe pain. We wish to examine the safety and speed of onset
      of hydromorphone using such a protocol.

      Our general thought is that to develop more evidence based practice, we need to generate more
      practice based evidence. This study attempts to do this as it is practiced based and very
      practical. We wish to take the drug as it comes (2mg Dilaudid in an ampule) and use all of
      it, thus alleviating the need to waste the excess opioid (and alleviating the need to find a
      second person to witness the wasting). We also wish to use a weight cutoff that everyone can
      remember (150 lbs). We believe that this protocol will provide greater pain relief and help
      address the issue of inadequate pain treatment, or &quot;oligoanalgesia&quot;, that is prominent in the
      literature (Sobel 2002, Wilson, 1989, Goldfrank 2000).

      Finally, in our multiple studies of pain conducted in the ED, we have found a relatively high
      rate of refusal to receive pain medication. We think this may represent a component to the
      problem of oligoanalgesia that is widespread in the ED. We wish to investigate the reasons
      for patient refusal to receiving parental opioid medications (fear of addiction, side
      effects, etc).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Requiring Naloxone</measure>
    <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
    <description>Naloxone is a reversal agent - a medication that reverses the effects of another. Hydromorphone is an opiate pain medication that acts as a depressant to the body, thereby slowing it down. A large slow down is dangerous, as it can cause the breathing rate to slow down too much and prevent enough oxygen from entering the body and reaching the brain, resulting in death. Naloxone is a medication that blocks the receptors binding opiate pain medication and reversing the body's reaction to the hydromorphone, allowing body processes to return to normal speeds, including the breathing rate. The use of naloxone in the study indicates that the participant received too much pain medication or reacted more strongly than the average person, requiring the rescue medication to reverse the negative effects. The number of participants who required naloxone is assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Respiratory Rate Lower Than 12 Breaths Per Minute</measure>
    <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
    <description>Normal respiratory rate ranges from 12 to 20 breaths per minute. The decreased respiration results in a decreased amount of oxygen entering the body and therefore low amount of oxygen supplied to the brain. Prolonged oxygen deprivation can result in injury or death. Respiratory rates lower than 12 breaths per minute is a sign of distress. Number of participants experiencing a respiratory rate lower than 12 breaths per minute is measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Systolic Blood Pressure Less Than 90 mmHg</measure>
    <time_frame>Immediately after infusion, up to 120 minutes post infusion</time_frame>
    <description>Normal systolic blood pressure is approximately 120 mmHg. A low systolic blood pressure indicates blood, and therefore oxygen, are not being distributed around the body properly. This leads to a decreased amount of oxygen for the body to use and can result in injury or death if prolonged or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Desaturation Measured Over 2-hour Time Frame</measure>
    <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
    <description>blood oxygen saturation less than 95% is considered oxygen desaturation. Blood oxygen saturation is normally above 95%. Oxygen desaturation of less than 90% is dangerous because there is less oxygen throughout the body for cellular energy. Prolonged or severe blood oxygen desaturation can result in injury or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation Measured Over 2-hour Time Frame</measure>
    <time_frame>baseline to 120 minutes post infusion</time_frame>
    <description>blood oxygen saturation is measured periodically from 1 minute to 120 minutes after the medication was infused</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>2 mg IV hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg IV hydromorphone administered over 2-3 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg IV hydromorphone</intervention_name>
    <arm_group_label>2 mg IV hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than 21 years

          2. Age less than 65 years of age

          3. Pain with onset within 7 days

          4. ED attending physician's judgment that patient's pain warrants use of morphine

          5. Normal mental status

        Exclusion Criteria:

          1. Prior use of methadone

          2. Use of other opioids or tramadol within past seven days

          3. Prior adverse reaction to hydromorphone.

          4. Chronic pain syndrome

          5. Alcohol intoxication

          6. SBP &lt;90 mm Hg

          7. Use of MAO inhibitors in past 30 days

          8. C02 measurement greater than 46
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew K Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 17, 2006</study_first_submitted>
  <study_first_submitted_qc>March 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2006</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>August 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2018</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Chang, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Acute</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Severe</keyword>
  <keyword>Hydromorphone</keyword>
  <keyword>Dilaudid</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2 mg IV Hydromorphone</title>
          <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Necessary Data Collected</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing data</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>29 participants had missing data and were excluded from analysis</population>
      <group_list>
        <group group_id="B1">
          <title>2 mg IV Hydromorphone</title>
          <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pain intensity</title>
          <description>Pain intensity is measured on a numerical rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>less than 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Final diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Abcess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary colic/cholecystitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diverticulitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Stone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonspecific abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyelonephritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small bowel obstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disposition</title>
          <description>Disposition is where the participant goes after the ED. Discharge means they are well enough to leave the hospital. Admit means they were admitted to the hospital for an inpatient stay. Against medical advice means that although the physician recommended they come into the hospital for an inpatient stay, the patient chose to leave the hospital and go against the recommendation of their doctor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Admitted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Against medical advice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Requiring Naloxone</title>
        <description>Naloxone is a reversal agent - a medication that reverses the effects of another. Hydromorphone is an opiate pain medication that acts as a depressant to the body, thereby slowing it down. A large slow down is dangerous, as it can cause the breathing rate to slow down too much and prevent enough oxygen from entering the body and reaching the brain, resulting in death. Naloxone is a medication that blocks the receptors binding opiate pain medication and reversing the body's reaction to the hydromorphone, allowing body processes to return to normal speeds, including the breathing rate. The use of naloxone in the study indicates that the participant received too much pain medication or reacted more strongly than the average person, requiring the rescue medication to reverse the negative effects. The number of participants who required naloxone is assessed.</description>
        <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Naloxone</title>
          <description>Naloxone is a reversal agent - a medication that reverses the effects of another. Hydromorphone is an opiate pain medication that acts as a depressant to the body, thereby slowing it down. A large slow down is dangerous, as it can cause the breathing rate to slow down too much and prevent enough oxygen from entering the body and reaching the brain, resulting in death. Naloxone is a medication that blocks the receptors binding opiate pain medication and reversing the body's reaction to the hydromorphone, allowing body processes to return to normal speeds, including the breathing rate. The use of naloxone in the study indicates that the participant received too much pain medication or reacted more strongly than the average person, requiring the rescue medication to reverse the negative effects. The number of participants who required naloxone is assessed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Respiratory Rate Lower Than 12 Breaths Per Minute</title>
        <description>Normal respiratory rate ranges from 12 to 20 breaths per minute. The decreased respiration results in a decreased amount of oxygen entering the body and therefore low amount of oxygen supplied to the brain. Prolonged oxygen deprivation can result in injury or death. Respiratory rates lower than 12 breaths per minute is a sign of distress. Number of participants experiencing a respiratory rate lower than 12 breaths per minute is measured.</description>
        <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Respiratory Rate Lower Than 12 Breaths Per Minute</title>
          <description>Normal respiratory rate ranges from 12 to 20 breaths per minute. The decreased respiration results in a decreased amount of oxygen entering the body and therefore low amount of oxygen supplied to the brain. Prolonged oxygen deprivation can result in injury or death. Respiratory rates lower than 12 breaths per minute is a sign of distress. Number of participants experiencing a respiratory rate lower than 12 breaths per minute is measured.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Systolic Blood Pressure Less Than 90 mmHg</title>
        <description>Normal systolic blood pressure is approximately 120 mmHg. A low systolic blood pressure indicates blood, and therefore oxygen, are not being distributed around the body properly. This leads to a decreased amount of oxygen for the body to use and can result in injury or death if prolonged or severe.</description>
        <time_frame>Immediately after infusion, up to 120 minutes post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Systolic Blood Pressure Less Than 90 mmHg</title>
          <description>Normal systolic blood pressure is approximately 120 mmHg. A low systolic blood pressure indicates blood, and therefore oxygen, are not being distributed around the body properly. This leads to a decreased amount of oxygen for the body to use and can result in injury or death if prolonged or severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Desaturation Measured Over 2-hour Time Frame</title>
        <description>blood oxygen saturation less than 95% is considered oxygen desaturation. Blood oxygen saturation is normally above 95%. Oxygen desaturation of less than 90% is dangerous because there is less oxygen throughout the body for cellular energy. Prolonged or severe blood oxygen desaturation can result in injury or death.</description>
        <time_frame>immediately after infusion, up to 120 minutes post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Measured Over 2-hour Time Frame</title>
          <description>blood oxygen saturation less than 95% is considered oxygen desaturation. Blood oxygen saturation is normally above 95%. Oxygen desaturation of less than 90% is dangerous because there is less oxygen throughout the body for cellular energy. Prolonged or severe blood oxygen desaturation can result in injury or death.</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at least 95% oxygen saturation, all time points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="62" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90-94% oxygen saturation, one or more times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>below 90% oxygen saturation, one or more times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation Measured Over 2-hour Time Frame</title>
        <description>blood oxygen saturation is measured periodically from 1 minute to 120 minutes after the medication was infused</description>
        <time_frame>baseline to 120 minutes post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation Measured Over 2-hour Time Frame</title>
          <description>blood oxygen saturation is measured periodically from 1 minute to 120 minutes after the medication was infused</description>
          <units>% oxygen saturation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="97" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Pain Intensity Assessed Over 2-hour Time Frame</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain possible&quot;). Participants are asked to rate their pain periodically over a 2 hour time period following infusion of the medication.</description>
        <time_frame>baseline up to 120 minutes after post infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg IV Hydromorphone</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Assessed Over 2-hour Time Frame</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS), from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain possible&quot;). Participants are asked to rate their pain periodically over a 2 hour time period following infusion of the medication.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minutes post infustion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 mg IV Hydromorphone</title>
          <description>2 mg IV hydromorphone administered over 2-3 minutes
2 mg IV hydromorphone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>excluding patients who were nauseated or had vomited at baseline, before receiving hydromorphone</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>excluding patients who were nauseated or had vomited at baseline, before receiving hydromorphone</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Rate &lt;12 breathes per minute</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Rate &lt;60 beats/min</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Systolic blood pressure &lt;90 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Chang, MD, MS</name_or_title>
      <organization>Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center</organization>
      <phone>718-920-7476</phone>
      <email>achang@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

